Aadi Bioscience, INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
Scott M. Giacobello, CHIEF FINANCIAL OFFICER of Aadi Bioscience, Inc., reported multiple transactions in common stock on September 15, 2026.
Bryan Ball, See remarks of Aadi Bioscience, Inc., reported multiple transactions in common stock on September 15, 2026.
David Dornan, Chief Scientific Officer of Aadi Bioscience, Inc., reported multiple transactions in common stock on September 15, 2026.
David James Lennon, CHIEF EXECUTIVE OFFICER and a Director of Aadi Bioscience, Inc., reported multiple transactions in common stock on September 15, 2026.
Margaret Dugan, Chief Medical Officer of Aadi Bioscience, Inc., reported multiple transactions in common stock on September 15, 2026.
David James Lennon, CHIEF EXECUTIVE OFFICER and a Director of Aadi Bioscience, Inc., reported multiple transactions in common stock on September 15, 2026.
Scott M. Giacobello, CHIEF FINANCIAL OFFICER of Aadi Bioscience, Inc., reported multiple transactions in common stock on September 15, 2026.
Margaret Dugan, Chief Medical Officer of Aadi Bioscience, Inc., reported multiple transactions in common stock on September 15, 2026.
David Dornan, Chief Scientific Officer of Aadi Bioscience, Inc., reported multiple transactions in common stock on September 15, 2026.
Bryan Ball, See remarks of Aadi Bioscience, Inc., reported multiple transactions in common stock on September 15, 2026.
Anupam Dalal, a Director of Aadi Bioscience, Inc., reported multiple transactions in common stock on May 14, 2026.
Director Zhao Baiteng was granted 38,040 stock options in Whitehawk Therapeutics, Inc. with an exercise price of $4.16.
Director Emma Reeve was granted 38,040 stock options in Whitehawk Therapeutics, Inc. with an exercise price of $4.16.
Director Richard E. Maroun was granted 38,040 stock options in Whitehawk Therapeutics, Inc. as part of an equity incentive plan.
Director Mohammad Hirmand of Whitehawk Therapeutics, Inc. was granted 38,040 stock options with an exercise price of $4.16.
Director Neil Desai was granted 38,040 stock options in Whitehawk Therapeutics, Inc. as part of an equity incentive plan.
Whitehawk Therapeutics director Caley Castelein was granted 38,040 stock options with an exercise price of $4.16.
Director Behzad Aghazadeh and associated entities reported the acquisition of 38,040 stock options in Whitehawk Therapeutics.
Margaret Dugan, Chief Medical Officer of Whitehawk Therapeutics, Inc., reported a transaction involving common stock.
Bryan Ball, Chief Technical Operations Officer at Whitehawk Therapeutics, Inc., reported the acquisition of 51,020 shares of common stock.
Scott M. Giacobello, Chief Financial Officer of Whitehawk Therapeutics, Inc., acquired 38,265 shares of common stock on May 14, 2026.
David James Lennon, CEO of Whitehawk Therapeutics, Inc., has acquired 51,021 shares of common stock.
Whitehawk Therapeutics, Inc. reports a Form 4 filing detailing a Director's acquisition of common stock and pre-funded warrants.
Avoro Capital Advisors acquired 6,377,714 pre-funded warrants in a private placement with Whitehawk Therapeutics.
Whitehawk Therapeutics CFO Scott M. Giacobello sold 218,600 shares to cover tax obligations related to RSU vesting.
Chief Technical Operations Officer Bryan Ball sold 118,849 shares of Whitehawk Therapeutics to cover tax obligations.
Bryan Ball, Chief Technical Operations Officer at Whitehawk Therapeutics, Inc., reported transactions involving the sale of company common stock.
Whitehawk Therapeutics CEO David James Lennon reported a sale of 14,500 common shares for $3.38 each, totaling $49,010, to cover tax obligations related to vested restricted stock units.
Whitehawk Therapeutics CEO David James Lennon reported transactions involving the sale of company stock to cover tax obligations related to vested restricted stock units.
David Dornan, Chief Scientific Officer of Whitehawk Therapeutics, Inc., was granted a significant stock option on April 1, 2026.